20401-90-5

Usage

Uses

Used in Medicinal Chemistry:
3-(1H-indol-3-yl)propanehydrazide is used as a pharmaceutical intermediate for the synthesis of new drugs. Its unique structure and hydrazide functionality make it a promising candidate for the development of various therapeutic agents.
Used in Drug Discovery:
3-(1H-indol-3-yl)propanehydrazide is used as a building block in the development of new drugs. Its versatility allows for the synthesis of diverse organic compounds with potential applications in the pharmaceutical industry.
Further research and investigation into the properties and potential applications of 3-(1H-indol-3-yl)propanehydrazide are warranted to fully explore its capabilities and contributions to the field of medicinal chemistry and drug discovery.

Upstream product

• 5548-09-4 Methyl indole-3-propionate 
• 40641-03-0 ethyl 3-(indol-3-yl)propanoate 
• 830-96-6 Indole-3-propionic acid 

Downstream Products

• 937247-23-9 tert-butyl (R)-1-(5-(2-(1H-indol-3-yl)ethyl)-4-(2,4-dimethoxybenzyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethylcarbamate 
• 937248-07-2 C₃₆H₄₀N₆O₄ 
• 937248-10-7 C₃₅H₃₈N₆O₃ 
• 937248-16-3 (R)-tert-butyl 1-(5-(2-(1H-indol-3-yl)ethyl)-4-(4-methoxybenzyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethylcarbamate 
• 937248-21-0 C₃₅H₃₈N₆O₃ 
• 937248-25-4 C₃₄H₃₆N₆O₂ 
• 937248-29-8 C₃₄H₃₅BrN₆O₂ 
• 937248-34-5 C₃₄H₃₅FN₆O₂ 
• 937248-38-9 C₃₄H₃₄Cl₂N₆O₂ 
• 937248-43-6 C₃₅H₃₈N₆O₂ 
• 937248-54-9 C₄₁H₄₂N₆O₂ 
• 1157858-21-3 3-(1H-indol-3-yl)-propionic acid [1-(4-fluoro-phenyl)-meth-(E)-ylidene]-hydrazide 
• 676586-82-6 N'-(4-nitrobenzylidene)-3-(1H-indol-3-yl)propanehydrazide 
• 1449036-13-8 5-(3-(1H-indol-3-yl)ethyl)-2-(4-nitrophenyl)-1,3,4-oxadiazole 

Relevant academic research and scientific papers

New class of hybrids based on chalcone and melatonin: a promising therapeutic option for the treatment of colorectal cancer

Considering that conventional chemotherapy provides only a limited increase of overall survival for patients with colorectal cancer (CRC), and resistance is a major cause of therapeutic failure, the emergence of new therapies is needed. Development of dif

4-Alkyl-1,2,4-triazole-3-thione analogues as metallo-β-lactamase inhibitors

In Gram-negative bacteria, the major mechanism of resistance to β-lactam antibiotics is the production of one or several β-lactamases (BLs), including the highly worrying carbapenemases. Whereas inhibitors of these enzymes were recently marketed, they only target serine-carbapenemases (e.g. KPC-type), and no clinically useful inhibitor is available yet to neutralize the class of metallo-β-lactamases (MBLs). We are developing compounds based on the 1,2,4-triazole-3-thione scaffold, which binds to the di-zinc catalytic site of MBLs in an original fashion, and we previously reported its promising potential to yield broad-spectrum inhibitors. However, up to now only moderate antibiotic potentiation could be observed in microbiological assays and further exploration was needed to improve outer membrane penetration. Here, we synthesized and characterized a series of compounds possessing a diversely functionalized alkyl chain at the 4-position of the heterocycle. We found that the presence of a carboxylic group at the extremity of an alkyl chain yielded potent inhibitors of VIM-type enzymes with Ki values in the μM to sub-μM range, and that this alkyl chain had to be longer or equal to a propyl chain. This result confirmed the importance of a carboxylic function on the 4-substituent of 1,2,4-triazole-3-thione heterocycle. As observed in previous series, active compounds also preferentially contained phenyl, 2-hydroxy-5-methoxyphenyl, naphth-2-yl or m-biphenyl at position 5. However, none efficiently inhibited NDM-1 or IMP-1. Microbiological study on VIM-2-producing E. coli strains and on VIM-1/VIM-4-producing multidrug-resistant K. pneumoniae clinical isolates gave promising results, suggesting that the 1,2,4-triazole-3-thione scaffold worth continuing exploration to further improve penetration. Finally, docking experiments were performed to study the binding mode of alkanoic analogues in the active site of VIM-2.

COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER

This disclosure relates to certain compounds that are effective in the treatment of a Rac-GTPase mediated disorder (e.g., acute lymphoblastic or chronic myelogenous leukemia), as well as methods for the manufacture of and the use of these compounds (e.g.,

A double-indole hydrazone compound and use thereof

The invention provides a bisindole acylhydrazone compound shown as the formula I or salt, hydrate or crystals, accepted in the pharmacy, of the bisindole acylhydrazone compound. According to the bisindole acylhydrazone compound, R does not exist or is selected from alkylene of C1-5. The bisindole acylhydrazone compound has a certain antibacterial activity, and can serve as potential antibiotics or a daily chemical product. What is beyond the expectation is that compounds 4e-4h and compounds 4a-4c are quite similar in structure, the antibacterial activity of the compounds 4e-4h and the antibacterial activity of the compounds 4a-4c are obviously better than that of other compounds, particularly, the activity of the compound 4h is best and is remarkably better than that of compounds 4e-4g. The formula I is shown in the specification.

Indole hydrazone compounds

The invention provides a compound of the formula I as shown in the description. In the formula, R is connected with the carbon atom at the 2nd or 3rd site of indolyl and is selected from none or C1-3 alkylene. Molecular tweezers of bisindole acylhydrazone have a good recognition cooperation function on inspected malic acid, tartaric acid, ascorbic acid and tryptophan, and have no recognition cooperation function on other inspected organic acids such as lactic acid, oxalic acid, tyrosine, histidine and serine. Therefore, due to the selective recognition property of a molecular tweezers receptor has the potential to be applied to fields such as analysis and separation of relevant organic acids in biological medicines, and transportation of organic acid medicines.

Microwave-assisted synthesis and molecular recognition properties of novel indole acylhydrazone receptors

Indole acylhydrazones were synthesised in high yields under microwave irradiation By using indole carboxylic acid and 1,4-benzenedialdehyde as starting materials. Their structures were characterised by 1H NMR, IR, MS spectra and elemental analysis. Selective recognition properties of these receptors have been investigated by UV-Vis spectra titration indicating that these receptors can form 1:1 supramolecular complexes with malic acid, tartaric acid, ascorbic acid and tryptophan.

Synthesis and biological screening of 5-(alkyl(1H-indol-3-yl))-2- (substituted)-1,3,4-oxadiazoles as antiproliferative and anti-inflammatory agents

A series of 5-(alkyl(1H-indol-3-yl))-2-(substituted)-1,3,4-oxadiazoles were efficiently synthesized by oxidative cyclisation of N0 -benzylidene-(1H-indol- 3-yl)alkane hydrazides using di(acetoxy)iodobenzene. N0 -Benzylidene-(1H-indol- 3-yl)alkane hydrazid

NOVEL 1,2,4-TRIAZOLE DERIVATIVES AND PROCESS OF MANUFACTURING THEREOF

The invention provides 1,2,4-triazole compounds, compositions containing those compounds, methods of treating diseases and/or disorders with those compounds and processes of manufacturing 1,2,4-triazole compounds.

N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS

This invention relates to N-acylhydrazone derivatives (I), which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases

Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1

A new series of growth hormone secretagogue (GHS) analogues based on the 1,2,4-triazole structure were synthesized and evaluated for their in vitro binding and their ability to stimulate intracellular calcium release to the cloned hGHS-1a ghrelin receptor expressed in LLC PK-1 cells. We have synthesized potent ligands of this receptor, some of them behaving as agonists, partial agonists, or antagonists. Some compounds among the most potent, i.e., agonist 29c (JMV2873), partial agonists including 21b (JMV2810), antagonists 19b (JMV2866) and 19c (JMV2844), were evaluated for their in vivo activity on food intake, after sc injection in rodents. Some compounds were found to stimulate food intake like hexarelin; some others were identified as potent hexarelin antagonists in this assay. Among the tested compounds, 21b was identified as an in vitro ghrelin receptor partial agonist, as well as a potent in vivo antagonist of hexarelin-stimulated food intake in rodents. Compound 21b was without effect on GH release from rat. However, in this series of compounds, it was not possible to find a clear correlation between in vitro and in vivo results.